JP2021502414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502414A5 JP2021502414A5 JP2020544357A JP2020544357A JP2021502414A5 JP 2021502414 A5 JP2021502414 A5 JP 2021502414A5 JP 2020544357 A JP2020544357 A JP 2020544357A JP 2020544357 A JP2020544357 A JP 2020544357A JP 2021502414 A5 JP2021502414 A5 JP 2021502414A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- expanded
- complex
- tumor antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022060497A JP7420856B2 (ja) | 2017-11-08 | 2022-03-31 | Ｔ細胞を製造する組成物及び方法 |
| JP2024001623A JP7728373B2 (ja) | 2017-11-08 | 2024-01-10 | Ｔ細胞を製造する組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583229P | 2017-11-08 | 2017-11-08 | |
| US62/583,229 | 2017-11-08 | ||
| US201762588590P | 2017-11-20 | 2017-11-20 | |
| US62/588,590 | 2017-11-20 | ||
| US201862618445P | 2018-01-17 | 2018-01-17 | |
| US62/618,445 | 2018-01-17 | ||
| US201862737625P | 2018-09-27 | 2018-09-27 | |
| US62/737,625 | 2018-09-27 | ||
| PCT/US2018/059896 WO2019094642A1 (en) | 2017-11-08 | 2018-11-08 | T cell manufacturing compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022060497A Division JP7420856B2 (ja) | 2017-11-08 | 2022-03-31 | Ｔ細胞を製造する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502414A JP2021502414A (ja) | 2021-01-28 |
| JP2021502414A5 true JP2021502414A5 (https=) | 2021-12-16 |
| JP7054418B2 JP7054418B2 (ja) | 2022-04-13 |
Family
ID=66438061
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544357A Active JP7054418B2 (ja) | 2017-11-08 | 2018-11-08 | Ｔ細胞を製造する組成物及び方法 |
| JP2022060497A Active JP7420856B2 (ja) | 2017-11-08 | 2022-03-31 | Ｔ細胞を製造する組成物及び方法 |
| JP2024001623A Active JP7728373B2 (ja) | 2017-11-08 | 2024-01-10 | Ｔ細胞を製造する組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022060497A Active JP7420856B2 (ja) | 2017-11-08 | 2022-03-31 | Ｔ細胞を製造する組成物及び方法 |
| JP2024001623A Active JP7728373B2 (ja) | 2017-11-08 | 2024-01-10 | Ｔ細胞を製造する組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11162072B2 (https=) |
| EP (1) | EP3706784A4 (https=) |
| JP (3) | JP7054418B2 (https=) |
| KR (2) | KR20230008254A (https=) |
| CN (2) | CN111867618B (https=) |
| BR (1) | BR112020008927A2 (https=) |
| CA (1) | CA3081840A1 (https=) |
| SG (1) | SG11202004116QA (https=) |
| WO (1) | WO2019094642A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| CN112584852A (zh) * | 2018-06-19 | 2021-03-30 | 百欧恩泰美国公司 | 新抗原及其用途 |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| JP7668226B2 (ja) | 2019-03-30 | 2025-04-24 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用 |
| AR118859A1 (es) * | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| CN110514845B (zh) * | 2019-08-22 | 2022-09-27 | 深圳新合睿恩生物医疗科技有限公司 | 一种肿瘤新生抗原免疫原性检测方法及检测平台 |
| US20230032934A1 (en) * | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| GB201918290D0 (en) | 2019-12-12 | 2020-01-29 | Achilles Therapeutics Ltd | Method |
| US20230052157A1 (en) | 2019-12-12 | 2023-02-16 | Achilles Therapeutics Uk Limited | Method for obtaining nucleic acid for sequencing |
| CN115461062A (zh) | 2020-04-28 | 2022-12-09 | 阿基里斯治疗英国有限公司 | T细胞疗法 |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3176826A1 (en) * | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| MX2023001815A (es) * | 2020-08-13 | 2023-04-11 | Biontech Us Inc | Metodos y composiciones de fabricacion de celulas t. |
| CA3189269A1 (en) | 2020-08-13 | 2022-02-17 | Vikram JUNEJA | Ras neoantigens and uses thereof |
| WO2022115641A2 (en) * | 2020-11-25 | 2022-06-02 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| US20250195659A1 (en) * | 2021-10-15 | 2025-06-19 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
| KR20250161543A (ko) * | 2023-03-15 | 2025-11-17 | 가부시키가이샤 가이아바이오메디신 | 세포를 현탁하기 위한 액 및 그 이용 |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE69333433T2 (de) | 1992-04-01 | 2004-12-02 | The Rockefeller University | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
| WO1994003205A1 (en) | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| BR9406652A (pt) | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU2003270311A1 (en) | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| WO2006015497A1 (en) | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
| WO2006110582A1 (en) * | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| WO2009045308A2 (en) | 2007-10-03 | 2009-04-09 | Fred Hutchinson Cancer Research Center | Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| DE13746292T1 (de) | 2012-02-10 | 2014-10-30 | Hakushinkouseikai Foundation | Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen |
| US20150104441A1 (en) | 2013-10-11 | 2015-04-16 | Oslo Universitetssykehus Hf | Identification of disease-driving antigens |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CN106062185A (zh) * | 2014-04-24 | 2016-10-26 | 美天旎生物技术有限公司 | 用于自动生成遗传修饰的t细胞的方法 |
| CN103923880B (zh) | 2014-05-08 | 2016-03-30 | 成都百赛泰科生物科技有限公司 | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 |
| JP6599450B2 (ja) | 2014-10-02 | 2019-10-30 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| AU2016306408B2 (en) | 2015-08-10 | 2021-02-11 | Toray Industries, Inc. | Immune inducer |
| US20190119350A1 (en) | 2015-09-09 | 2019-04-25 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
| US10221249B2 (en) | 2015-09-10 | 2019-03-05 | Affigen, Llc | Method of making patient specific anti-idiotype antibodies |
| CA3021634A1 (en) | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| BR112020005552A2 (pt) | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| KR20240091046A (ko) | 2018-12-21 | 2024-06-21 | 바이오엔테크 유에스 인크. | Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템 |
| AR118859A1 (es) | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
| MX2023001815A (es) | 2020-08-13 | 2023-04-11 | Biontech Us Inc | Metodos y composiciones de fabricacion de celulas t. |
| US20250195659A1 (en) | 2021-10-15 | 2025-06-19 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| CN120641112A (zh) | 2022-12-09 | 2025-09-12 | 百欧恩泰美国公司 | T细胞制备组合物和方法 |
-
2018
- 2018-11-08 SG SG11202004116QA patent/SG11202004116QA/en unknown
- 2018-11-08 WO PCT/US2018/059896 patent/WO2019094642A1/en not_active Ceased
- 2018-11-08 CN CN201880085909.8A patent/CN111867618B/zh active Active
- 2018-11-08 CN CN202510236442.4A patent/CN120519386A/zh active Pending
- 2018-11-08 KR KR1020227046367A patent/KR20230008254A/ko not_active Ceased
- 2018-11-08 JP JP2020544357A patent/JP7054418B2/ja active Active
- 2018-11-08 KR KR1020207016435A patent/KR102484433B1/ko active Active
- 2018-11-08 CA CA3081840A patent/CA3081840A1/en active Pending
- 2018-11-08 BR BR112020008927-3A patent/BR112020008927A2/pt unknown
- 2018-11-08 EP EP18875943.5A patent/EP3706784A4/en active Pending
-
2020
- 2020-01-06 US US16/735,555 patent/US11162072B2/en active Active
-
2021
- 2021-10-05 US US17/494,633 patent/US12258581B2/en active Active
-
2022
- 2022-03-31 JP JP2022060497A patent/JP7420856B2/ja active Active
-
2024
- 2024-01-10 JP JP2024001623A patent/JP7728373B2/ja active Active
-
2025
- 2025-01-27 US US19/038,215 patent/US20250188414A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502414A5 (https=) | ||
| Bol et al. | Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity | |
| JP2024041873A5 (https=) | ||
| US20220016164A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
| Butterfield et al. | Adenovirus MART-1–engineered autologous dendritic cell vaccine for metastatic melanoma | |
| Lesterhuis et al. | Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests | |
| JP2014521657A (ja) | 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法 | |
| KR20130024888A (ko) | 폴리펩티드 | |
| CN103570818A (zh) | 肿瘤抗原性多肽及其作为肿瘤疫苗的用途 | |
| JP2018511320A (ja) | 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法 | |
| CN115702927A (zh) | 一种广谱性肿瘤疫苗增效的组合物 | |
| Batich et al. | Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma | |
| JP6602377B2 (ja) | 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途 | |
| JP2022538609A5 (https=) | ||
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| Daudelin et al. | IL‐6 production by dendritic cells is dispensable for CD8+ memory T‐cell generation | |
| WO2017177908A1 (zh) | Pd-l1和pd-l2重组蛋白及其用途 | |
| Zhang et al. | Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous α fetoprotein in mice | |
| US9089593B2 (en) | Dendritic cell tumor injection (DCTI) therapy | |
| Kim et al. | Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination | |
| US8110654B2 (en) | T cell epitope peptides of ovarian cancer anti-idiotypic antibody 6B11 and use thereof | |
| CN119486753A (zh) | 个体化癌症表位及其使用方法 | |
| Hoang-Minh et al. | Adoptive cell therapy for glioma | |
| CN103254313B (zh) | 组合的ctl抗原表位及其应用 | |
| US20020065241A1 (en) | Antigenic peptide concatomers |